美国通胀：延续温和 宏 观 快 报 点 评 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 2025 年 12 月美国通胀数据点评 本报告导读： 12 月美国通胀并未出现市场此前所担忧的补偿性反弹，核心 CPI 增速反而不及预期。 结构上来看核心商品通胀温和，核心服务通胀有所回升。短期内美国通胀压力或仍 偏温和，不会对市场情绪以及美联储货币政策决定带来过多扰动。 投资要点： 宏 观 研 究 宏观研究 /[Table_Date] 2026.01.14 2026-01-14 [Table_Summary] 美国 12 月通胀：反弹幅度不及预期。数据公布前，市场普遍认为由 于政府关门导致 11 月通胀数据被低估，12 月通胀数据会出现补偿 性反弹。但 12 月美国 CPI 同比增速维持 2.7%，与 11 月持平；环比 增速维持 0.3%，与 9 月持平，并未出现明显回升。此外，核心 CPI 增速反而低于预期。其中核心 CPI 同比 2.6%（市场预期 2.7%，前值 2.6%），核心 CPI 环比 0.2%（市场预期 0.3%）。总体来看，12 月通胀 数据显示美国当前通胀压力仍较温和。 结构：商品偏弱 ...

研究报告 Research Report 14 Jan 2026 首次覆盖：重组胶原蛋白领军者，2026 战略转型开启品牌化新篇章 Recombinant Collagen Leader: 2026 Strategy Ushers in Brand New Era: Initiation [Table_yemei1] 观点聚焦 Investment Focus [Table_Info] 首次覆盖优于大市 Initiate with OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$35.74 目标价 HK$43.60 HTI ESG 3.1-3.9-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$38.27bn / US$4.91bn 日交易额 (3 个月均值) US$58.76mn 发行股票数目 1,071mn 自由流通股 (%) 45% 1 年股价最高最低值 HK$84.90-HK$33.28 注：现价 HK$35.74 为 2026 年 01 月 13 日收盘价 资料来源： Factset ...

开年经济温和回暖 宏观研究 /[Table_Date] 2026.01.11 ——国内高频指标跟踪（2026 年第 2 期） 本报告导读： 政策支撑下内需仍具韧性，外需与生产改善，经济向上动能有所积聚。 投资要点： 证 券 研 究 宏 观 研 究 宏 观 周 报 请务必阅读正文之后的免责条款部分 报 告 2026-01-13 [Table_Summary] 近期光伏与储能领域密集释放"反内卷"相关政策信号，出口退税逐 步取消、座谈会研究部署进一步规范行业竞争秩序。短期光伏等行 业盈利或承压、出清加速，中期供需格局改善，具备技术壁垒、成 本优势及海外渠道能力的龙头企业有望率先受益。 上周高频数据显示，消费方面，汽车消费因以旧换新补贴升温，服 务消费在元旦假期后边际走弱。投资方面，专项债发行前置，有望 助力一季度基建投资止跌回稳，但地产仍偏弱，建材链实物指标季 节性走低。外贸景气度改善，出口量价均上行。生产整体回暖，钢 铁、石化、氯碱开工率普遍上行。物价方面，消费品价格偏弱，工 业品价格多数回升，有色链和碳酸锂价格持续上涨。流动性层面， 资金利率小幅上行，美元因地缘事件引发市场避险情绪升值，人民 币相应小幅贬值。 ...

宏 观 研 究 美国：消费者信心持续修复 宏观研究 /[Table_Date] 2026.01.11 2026-01-13 宏 观 周 报 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 ——海外经济政策跟踪 本报告导读： 本周高频数据显示，美国经济仍具有韧性，短期降息预期有所回落，通胀预期小幅 回升。特朗普在多项对外议题上释放较强硬的干预信号，全球地缘不确定性继续抬 升，大宗价格持续上涨。后续关注特朗普对美联储主席的提名情况。 投资要点： [Table_Summary] 全球大类资产表现。本周（2026.1.2-2026.1.9），风险资产多数上涨。 主要经济体股市多数上涨，大宗商品价格大多上涨。债市方面，10 年期美债收益率上涨 5.7%，国内 10Y 国债期货价格下跌 0.1%，中 债总全价指数下降 0.2%。外汇市场方面，美元指数较前一周上涨 0.7%，人民币升值，美元兑人民币汇率收 6.98，日元贬值。 经济：美国方面：2025 年 12 月美国失业率、制造业 PMI 回落，服 务业 PMI 回升，1 月消费者信心持续修复，通胀预期小幅回升。欧 洲方面：通胀有所回落。 政策：美国方面：就业 ...

1. Report Industry Investment Rating No relevant content provided. 2. Core View of the Report In Q4 2025, the new - issue market of public funds cooled down, but the issuance volume of FOF increased against the trend, and diversified allocation became the main development direction [1]. 3. Summary According to the Directory 3.1 Whole - Market Overview - **New - issue Quantity and Scale Declined Quarter - on - Quarter**: In Q4 2025, 406 new funds were established, with a total raised scale of about 285.434 billion yuan and an average raised scale of about 703 million yuan. Compared with Q3 2025, the number of new - issue funds decreased by 71, the new - issue scale decreased by about 93.427 billion yuan, and the average issuance scale dropped by 11.48% quarter - on - quarter. The new - issue scale of equity funds and fixed - income funds decreased, while that of FOF increased significantly [3][6]. - **Distribution of New - issue Fund Types**: The proportion of the new - issue scale of FOF increased significantly. In Q4 2025, the new - issue scale of equity funds accounted for 49.71%, and that of fixed - income funds accounted for 26.29%, while the new - issue scale of FOF/MOM accounted for 15.85%, a significant increase of about 14.13 percentage points compared with the previous quarter [14]. - **All New - issue Funds Were Successfully Raised, and Subscription Days Slightly Extended**: In Q4 2025, all new - issue funds were successfully raised, and the average subscription days were 16.7 days, slightly higher than that in Q3 2025 but still at a relatively low level in the past three years [28][31]. 3.2 Product Development Trend Analysis - **Equity Products**: - **Passive Equity Funds**: In Q4 2025, 183 index equity funds were established, with a total issuance scale of about 81.679 billion yuan. The number and scale of new - issue funds decreased significantly compared with Q3 2025, and the average issuance scale also decreased [35]. - **Active Equity Funds**: In Q4 2025, 106 active equity funds were established, with a total raised scale of about 60.218 billion yuan, accounting for 42.44% of equity funds. The number, scale, and scale proportion of new - issue funds continued to rise [42]. - **Fixed - Income Products**: In Q4 2025, 61 fixed - income funds were newly issued, with a total raised scale of about 75.035 billion yuan, a decrease of 25 in number and about 66.989 billion yuan in scale compared with Q3 2025, a quarter - on - quarter decline of 47.17% [46]. - **FOF**: In Q4 2025, 42 FOF were established, with a total raised scale of about 45.246 billion yuan, a significant increase of about 38.714 billion yuan quarter - on - quarter. The average raised scale was about 1.077 billion yuan, a quarter - on - quarter increase of 693 million yuan. FOF products are evolving towards diversified allocation [52][53]. - **QDII Products**: In Q4 2025, 6 new QDII funds were established. Two Brazilian ETFs, Huaxia Bradesco Brazil Ibovespa ETF and E Fund Itau Brazil IBOVESPA ETF, were over - subscribed during the issuance process, indicating that the Brazilian market is attracting investors' attention [59]. - **Mutual Recognition Products**: In Q4 2025, 1 mutual recognition fund, BOC Hong Kong Global Equity Fund, was newly established, with an issuance scale of about 1.524 billion yuan, which is a stock - type fund [61].

Investment Rating - The report maintains a positive outlook on the development of dual and triple antibodies in multiple myeloma (MM) and recommends monitoring the progress of TCE monotherapy and combination therapies in MM, including the EMD population [1][15]. Core Insights - The 67th ASH Annual Meeting highlighted significant advancements in hematology, particularly in the treatment of multiple myeloma, diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [31]. - In multiple myeloma, the Tec-Dara combination therapy demonstrated a 36-month overall survival (OS) rate of 83.3%, significantly higher than the 65.0% in the control group, with a hazard ratio (HR) of 0.46 [32]. - The MSD ROR1 ADC showed promising first-line potential in DLBCL, with 24-month OS and progression-free survival (PFS) rates of 94% and 84%, respectively, outperforming existing treatments [33]. - Eli Lilly's Pirto showed improved PFS and OS trends compared to BR, but the executive admitted it may not become the first-line choice for CLL/SLL due to limited follow-up data and current treatment practices favoring covalent BTK inhibitors [34]. Summary by Sections 1. R/R MM: Focus on Dual/Triple Antibodies and TCE Therapies - Johnson & Johnson's BCMA/CD3+daratumumab therapy received FDA's "National Priority Voucher," reducing review time to 1-2 months, showing excellent efficacy in high-risk patients [7][15]. - IBI3003 from Innovent demonstrated an overall response rate (ORR) of 83.3% in high-risk patients, with a 100% minimal residual disease (MRD) negative rate in those achieving complete response (CR) [16]. - AstraZeneca's AZD0120 (BCMA/CD19 CAR-T) is projected to exceed $5 billion in sales, with a 100% ORR in treated patients [20][21]. 2. DLBCL: MSD ROR1 ADC Shows First-Line Potential - The MSD ROR1 ADC demonstrated a 24-month OS rate of 94% and a PFS rate of 84%, outperforming R-CHOP and Pola-CHP treatments [22][23]. - In high-risk populations, the ORR was 75% for patients with extramedullary disease (EMD), with a 100% ORR in the 1200 µg/kg dose group [23]. 3. CLL/SLL: Pirto May Not Become First-Line Choice - Pirto vs BR showed a 24-month PFS of 93.4% vs 70.7%, but the data is still immature, with a median follow-up of 28 months [25][27]. - The safety profile of Pirto indicated a 40% incidence of grade 3 or higher treatment-emergent adverse events (TEAEs), compared to 67.4% for BR [25][27].

Investment Rating - The report assigns an "Outperform" rating to the company, with a target price of 11.52 RMB based on a 15x PE for 2026, resulting in a target market value of 187.5 billion RMB [1][16]. Core Insights - The company is positioned as a leading player in textile trade and the electrolyte sector, benefiting from the global restructuring of consumer goods supply chains and the recovery of the new energy industry. The core trading business maintains steady growth through global capacity layout, while the chemical new materials segment is expected to contribute to earnings elasticity due to increased orders from battery clients and improved supply structure [4][13]. Financial Summary - The company forecasts total revenue for 2025-2027 to be 398.6 billion, 413.3 billion, and 425.4 billion RMB, with year-on-year growth rates of +2.3%, +3.7%, and +2.9% respectively. The net profit attributable to the parent company is projected to be 11.93 billion, 12.50 billion, and 13.07 billion RMB, with growth rates of +7.9%, +4.8%, and +4.5% respectively [14][15]. Business Overview - The company operates primarily in the textile trade, which accounts for over 90% of its revenue. The chemical business, while facing challenges, still plays a role in the overall performance. The trading segment is expected to grow steadily, while the chemical segment is projected to recover gradually as market conditions improve [25][19]. Supply Chain Strategy - The company has shifted towards a "world supply chain integration" model, with significant investments in overseas production facilities, particularly in Southeast Asia and Africa. This strategy aims to mitigate external disruptions and ensure stable core orders [4][41]. New Energy and Materials Sector - The new energy materials segment, led by the subsidiary RuTai New Materials, is focused on lithium battery materials and organic silicon. The company anticipates a recovery in this sector as supply and demand dynamics improve, despite facing price pressures in the short term [20][4].

公 司 研 究 股票研究 /[Table_Date] 2026.01.09 2026-01-12 主业稳健，益生菌贡献新增长点 倍加洁(603059) | [Table_Finance] 财务摘要(百万元) | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入 | 1,067 | 1,299 | 1,511 | 1,729 | 1,966 | | (+/-)% | 1.6% | 21.8% | 16.3% | 14.5% | 13.7% | | 净利润(归母) | 93 | -77 | 99 | 132 | 174 | | (+/-)% | -4.9% | -183.6% | 228.4% | 33.4% | 31.3% | | 每股净收益(元) | 0.92 | -0.77 | 0.99 | 1.32 | 1.73 | | 净资产收益率(%) | 7.4% | -7.8% | 9.2% | 11.1% | 12.8% | | 市盈率(现价&最新股本摊薄) | 34.43 | — | 32 ...

Investment Rating - The report assigns an "Outperform" rating for the stock, expecting a relative return exceeding 10% over the next 12-18 months [13]. Core Insights - Fast Retailing's FY26Q1 results exceeded expectations with revenue of 10.28 trillion JPY, up 14.8% YoY, and net profit attributable to shareholders of 147.4 billion JPY, up 11.7% YoY [4][3]. - Uniqlo's revenue in Greater China increased, while all other regions achieved double-digit growth, with specific YoY revenue growth rates of +12.2% in Japan, +7.0% in Greater China, +22.1% in APAC, +30.4% in North America, and +34.3% in Europe [4][3]. - The company raised its FY26 guidance to revenue growth of +11.7% and net profit growth of +3.9%, anticipating double-digit growth in all international markets except Greater China [4][3]. Summary by Sections Financial Performance - FY26Q1 revenue was 10.28 trillion JPY, a 14.8% increase YoY, surpassing consensus estimates by 3.8% [4][3]. - Net profit attributable to shareholders was 147.4 billion JPY, an 11.7% increase YoY, also exceeding expectations [4][3]. - Inventory at the end of the period was 546.1 billion JPY, up 6.4% YoY [4][3]. Regional Performance - Uniqlo Japan's revenue grew by 12.2%, Greater China's by 7.0%, APAC by 22.1%, North America by 30.4%, and Europe by 34.3% YoY [4][3]. - Same-store sales in Japan increased by 11.0%, while Greater China's revenue in RMB grew by 5.5% [4][3]. Margin Analysis - Gross profit margin for FY26Q1 was 55.2%, up 0.8 percentage points YoY [4][3]. - Selling, general and administrative (SG&A) expense ratio was 35.2%, down 1.7 percentage points YoY [4][3]. - Net profit margin was 14.3%, a decrease of 0.4 percentage points YoY due to reduced foreign exchange gains [4][3]. Guidance and Outlook - The company expects all international markets, excluding Greater China, to achieve double-digit growth, with Japan's same-store sales projected to grow by 4% [4][3]. - The guidance for FY26 has been raised, reflecting confidence in continued growth despite potential short-term challenges [4][3].

股票研究 /[Table_Date] 2026.01.11 2026-01-12 反内卷再起，需求端预计 26 年开启上行周期 煤炭行业周报 本报告导读： 我们认为煤炭板块周期底部已经确认在 25Q2，供需格局已经显现了逆转拐点，下行 风险充分释放。 投资要点： 请务必阅读正文之后的免责条款部分 股 票 证 券 研 究 行 业 跟 踪 报 告 研 究 报 告 [table_Authors] [Table_Summary] 投资建议：从板块角度，继续关注红利的核心中国神华、陕西煤业、 中煤能源；以及兖矿能源、晋控煤业。 反内卷再推进，煤价有底，需求是核心。本周榆林增产保供产能推 出信息发布，我们认为相关涉及产能本身就处于未拿到核增批文的 停产状态，并不是满产产能 26 年退出，实际对于产量的影响不大。 供给变化的重点在查超产。我们认为期待增产保供产能退出为行业 带来供给明显收缩的可能性不高，并且导致 10-11 月国内产量大增 的核心问题还在超产，随着煤价高企导致各地产量大幅度环比回升， 各地政策能否加强监管和切实落实核减工作可能对于 26 年供给的 影响意义更大。11 月用电量持续加速增长再次展现电煤需求韧性 ...